SCHEMBL3530131

SCHEMBL3530131

Nc1ccc(I)c(OC(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.36
TSHR P16473 3/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 2/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
PDE2A O00408 1/20 0.32
APP P05067 1/20 0.31
EPHX2 P34913 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MPL P40238 1/20 0.30
NPC1 O15118 1/20 0.30
GMNN O75496 1/20 0.30
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9367414 0.81 GAA (0.40) GAATSHRGLAPOLBMAPK1
SCHEMBL6310104 0.79 GAA (0.39) GAATSHRGLAPOLBMAPK1
SCHEMBL31533760 0.79 GAA (0.39) GAATSHRGLAPOLBMAPK1
SCHEMBL714264 0.79 TSHR (0.48) GAATSHRGLAPOLBMAPK1
SCHEMBL734531 0.78 IDO1 (0.40) GAATSHRGLAPOLBMAPK1
SCHEMBL4849499 0.78 APP (0.49) GAATSHRGLAPOLBMAPK1
SCHEMBL23099860 0.78 GPR3 (0.40) PDE2AEPHX2KDM4EMPLSLC6A2
SCHEMBL1555931 0.76 CYP3A4 (0.46) GAATSHRGLAPOLBMAPK1
SCHEMBL22607085 0.76 TSHR (0.45) GAATSHRGLAPOLBMAPK1
SCHEMBL3534512 0.76 ALDH1A1 (0.46) GAATSHRGLAPOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7749992-B2 Compounds and methods for treating dislipidemia ELI LILLY AND COMPANY (US) 2010-07-06 US disclosed
EP-2098512-A1 Compounds and methods for treating dyslipidemia Eli Lilly & Company (US) 2009-09-09 EP disclosed
EP-1670768-B1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2009-09-09 EP disclosed
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia ELI LILLY AND COMPANY (US) 2007-11-01 US disclosed
EP-1670768-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005037796-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia APOB, CETP, PCSK9 GAA 445/4885TSHR 1024/4885GLA 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.